Daniel Spratt, MD

Clinical Contacts

734-936-4300

Administrative Contact

Kelley Forbes 734-647-9955

Biography

Dan Spratt, MD, is a leader in Genitourinary and CNS malignancies. In addition to his medical training at Vanderbilt University where he obtained his medical degree, he completed his radiation oncology residency at Memorial Sloan Kettering Cancer Center. He completed a research fellowship focused on androgen receptor signaling and non-invasive imaging in prostate cancer. Dr. Spratt is the Chief of the Genitourinary Radiotherapy Program, co-chairs the Genitourinary Division of Clinical Research, co-leads the LAPS cooperative group trial efforts, is the founder and director the Spine Oncology Program at the U of M, is the co-chair for the radiobiology and radiotherapy working group for the Prostate Cancer Foundation, serves as the lead on the American College of Radiology Unsealed Source national guidelines, and is a member of the NRG Genitourinary Core Committee for national clinical trials.

Dr. Spratt has published extensively in peer-reviewed journals on the topics of prostate cancer and CNS and spinal malignancies and has developed novel prognostic models to assess the aggressiveness of a patient’s cancer using not only clinical and pathologic features, but also genomic markers. His laboratory focuses on the interaction of androgen signaling and DNA repair in prostate cancer and methods to overcome radiation resistance. He runs novel phase I/II clinical trials to improve treatment outcomes and reduce side effects from cancer treatment.

Urology Today 2019: Radiation Therapy Advances and Technology Overview

Risk factors in prostate cancer

2019 Prostate Cancer Foundation interview

2018 ASCO interview

Areas of Interest

Translational and clinical research to identify novel biomarkers to individualize treatment for patients with cancer.
Use of both tissue based (i.e. –omic sequencing) approaches, and non-invasive approaches with functional and molecular imaging and blood based biomarkers to personalize therapy and monitor treatment resistance.

Clinical Interests

Genitourinary cancers (prostate, bladder, kidney, renal, urinary tract, and penile).
Central nervous system tumors of the brain and spine in both children and adults.
Stereotactic body radiation therapy (SBRT) for the treatment of prostate cancer and for tumors that have metastasized to the spine.

Honors & Awards

2016 Best of ASTRO Plenary Presentation; Identification and validation of intrinsic subtypes of prostate cancer
2016 ARRO Teacher of the Year Award, 2016
2016 Department of Defense Award- Prostate Cancer Research Program (2016-2019)
2014 ASTRO's 56th Annual Basic Science Abstract Award in the Biology
2014-2015 RSNA Research Roentgen Award for Outstanding Research
2013 European Urology's Award for Best Resident Publication
2012 World Congress of Brachytherapy- Travel Award - International
2010 AΩA (Alpha Omega Alpha) Honor Society Recipient
2009 Best of ASTRO Oral Presentation; A Novel Targeting Receptor for Radiation Assisted Drug Delivery
2009 StarBRITE (The Biomedical Research, Integration, Translation and Education portal), Microgrant recipient, Vanderbilt University Medical Center
2009 Winner of Vanderbilt Ingram Cancer Center poster competition, 2009
2006 Summa Cum Laude

Credentials

MD, Vanderbilt University School of Medicine
Board certification: Radiation Oncology

Grants

(PI: Spratt), 12/2016-12/2020, University of Michigan Cancer Center (CTRAC): A phase I trail of neoadjuvant stereotactic body radiotherapy prior to radical prostatectomy for high risk prostate cancerm Role: Principal Investigator.
(PI: Spratt), 11/2016-10/2022, Janssen Scientific through a consortium with Prostate Cancer Clinical Trial- 16-PA: acetate+Leuprolide with stereotactic, ultra-hypofractionated radiation (AASUR) in very high risk prostate cancer: A single arm, Phase II sStudy, Role: Principal Investigator.
PC151068: (PI: Spratt), 09/2016-09/2020, Army-Department of Defense: Genotoxic stress and androgen receptor signaling: Integration of dynamic non-invasive biomarkers post-radiotherapy in prostate cancer, Role: Principal Investigator.
R21CA191913-01A (PI: Veach), 12/2015-11/2017, National Institutes of Health: Auger electron radiotherapy of late-stage, castration-resistant prostate cancer using a brominated dihydrotestosterone analogue., Role: Co-Investigator.
14-PAF06860 (PI: Spratt), 07/2014-06/2019, Varian Medical Systems: A Phase II randomized trial comparing stereotactic body radiation therapy to radiofrequency ablation for the treatment of renal cell carcinoma Role: Princ(ipal Investigator.
U10 CA180801-05: UM LAPs -U10 Grant NIH-DHHS-US- 13-PAF03445 (PI: Zalupski) 04/2014-02/2019, Role: Co-Investigator with Effort.

Published Articles via PubMed

PAX8 expression and TERT promoter mutations in the nested variant of urothelial carcinoma: a clinicopathologic study with immunohistochemical and molecular correlates.

View More at PubMed

Published Articles or Reviews

Selected from 95 publications

Spratt DE, Evans MJ, Davis BJ, Doran MG, Lee MX, Shah N, Wongvipat J, Carnazza KE, Klee GG, Polkinghorn W, Tindall DJ, Lewis JS, Sawyers CL. Androgen receptor upregulation mediates radioresistance after ionizing radiation. Can Res, 75(22):4688-96, 2015. doi: 10.1158/0008-5472.CAN-15-0892.
Spratt DE, Chan T, Waldron L, Speers C, Feng FY, Ogunwobi OO, Osborne JR. Racial/Ethnic Disparities in genomic sequencing. JAMA Oncol, 2(8):1070-4,2016. doi: 10.1001/jamaoncol.2016.1854. PMID: 27366979
Lee JY¹, Spratt DE¹, Liss AL, McLaughlin PW. Vessel-sparing radiation and functional anatomy-based preservation for erectile function after prostate radiotherapy. Lancet Oncol, May;17(5):e198-208, 2016. doi: 10.1016/S1470-2045(16)00063-2. PMID: 27301047
Spratt DE, Zumsteg ZS, Feng FY, Tomlins SA. Translational and clinical implications of the genetic landscape of prostate cancer. Nat Rev Clin Oncol, Oct;13(10):597-610, 2016. doi: 10.1038/nrclinonc.2016.76. PMID: 27245282
Spratt DE, Soni PD, McLaughlin PW, Merrick GS, Stock RG, Blasko JC, Zelefsky MJ. American Brachytherapy Society Task Group Report: Combination of brachytherapy and external beam radiation for high-risk prostate cancer. Brachytherapy, Jan - Feb;16(1):1-12, 2017. doi: 10.1016/j.brachy.2016.09.006. PMID: 27771243
Spratt DE, Zaki BI, Franc BL, Hartford AC, Osborne JR. ACR Practice parameter for the performance of therapy with unsealed radiopharmaceutical sources. Clin Nucl Med, Feb;41(2):106-17, 2016. PMID: 26646993
Spratt DE, Osborne JR. Disparities in castration-resistant prostate cancer trials. J Clin Oncol, Apr 1;33(10):1101-3,2015. doi: 10.1200/JCO.2014.58.1751. PMID: 25691679